| Literature DB >> 31615045 |
Mikkel R Deutch1, Daniela Grimm2,3,4, Markus Wehland5, Manfred Infanger6, Marcus Krüger7.
Abstract
Licorice, today chiefly utilized as a flavoring additive in tea, tobacco and candy, is one of the oldest used herbs for medicinal purposes and consists of up to 300 active compounds. The main active constituent of licorice is the prodrug glycyrrhizin, which is successively converted to 3β-monoglucuronyl-18β-glycyrrhetinic acid (3MGA) and 18β-glycyrrhetinic acid (GA) in the intestines. Despite many reported health benefits, 3MGA and GA inhibit the 11-β-hydrogenase type II enzyme (11β-HSD2) oxidizing cortisol to cortisone. Through activation of mineralocorticoid receptors, high cortisol levels induce a mild form of apparent mineralocorticoid excess in the kidney and increase systemic vascular resistance. Continuous inhibition of 11β-HSD2 related to excess licorice consumption will create a state of hypernatremia, hypokalemia and increased fluid volume, which can cause serious life-threatening complications especially in patients already suffering from cardiovascular diseases. Two recent meta-analyses of 18 and 26 studies investigating the correlation between licorice intake and blood pressure revealed statistically significant increases both in systolic (5.45 mmHg) and in diastolic blood pressure (3.19/1.74 mmHg). This review summarizes and evaluates current literature about the acute and chronic effects of licorice ingestion on the cardiovascular system with special focus on blood pressure. Starting from the molecular actions of licorice (metabolites) inside the cells, it describes how licorice intake is affecting the human body and shows the boundaries between the health benefits of licorice and possible harmful effects.Entities:
Keywords: 11-β-dehydrogenase isozyme 2; glabridin; glycyrrhetinic acid; glycyrrhizin; hyperaldosteronism; hypertension; hypokalemia; licorice
Year: 2019 PMID: 31615045 PMCID: PMC6836258 DOI: 10.3390/foods8100495
Source DB: PubMed Journal: Foods ISSN: 2304-8158
Figure 1(a) Inflorescence of Glycyrrhiza glabra L.; (b) licorice-containing candies; (c) chemical structure of the prodrug glycyrrhizin (C42H62O16), the main active compound of licorice. The molecule consists of two molecules of glucuronic acid (left) that are linked to 18β-glycyrrhetinic acid; (d) chemical structure of glabridin (C20H20O4), a further bioactive licorice compound. Colors indicate molecule structures used in following schematics.
Figure 2Suggested glycyrrhizin metabolism. Dependent on the gut microbiome glycyrrhizin is stepwise hydrolyzed to 3β-monoglucuronyl-18β-glycyrrhetinic acid (3MGA) and 18β-glycyrrhetinic acid (GA; blue structure) in the intestines. Both 3MGA and GA were absorbed from the gut and transported systemically in the bloodstream. In the liver, they undergo hepatic biotransformation before products were excreted via bile. The flavonoid glabridin (yellow structure) is also absorbed from the gut and circulates in the blood in its aglycone form. The hepatic metabolization of glabridin is not shown here. Green hexagons: glucuronic acid. Parts of the figure were drawn by using pictures from Servier Medical Art (http://smart.servier.com), licensed under a Creative Commons Attribution 3.0 Unported License (https://creativecommons.org/licenses/by/3.0).
Figure 3(a) Correlation between licorice intake, the renin-angiotensin-aldosterone-system and licorice-induced adverse effects on the cardiovascular system. (b) Detailed pharmacodynamics of 3β-monoglucuronyl-18β-glycyrrhetinic acid (3MGA) and 18β-glycyrrhetinic acid (GA; blue structure) in the kidney. In addition to a possible direct binding to the mineralocorticoid receptor (MR), 3MGA and GA have inhibiting effects on 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2) and 5β-reductase. 11β-HSD2 converts cortisol to cortisone; 5β-reductase is involved in the degradation of aldosterone in the liver. Inhibition of both enzymes contributes to apparent mineralocorticoid excess. The insert shows the localization of the processes within the Henle loop. ACE: angiotensin converting enzyme, ENaC: epithelial sodium channel, ET-1: endothelin 1, HRE: hormone response element, NAD(H): nicotinamide adenine dinucleotide, NO: nitric oxide, ROMK: renal outer medullary potassium channel. Parts of the figure were drawn by using pictures from Servier Medical Art (http://smart.servier.com), licensed under a Creative Commons Attribution 3.0 Unported License (https://creativecommons.org/licenses/by/3.0).
Studies investigating the effects of licorice intake on the human cardiovascular system.
| Author (Year), Country | Study Design |
| Drug | Daily Dose | Duration | Relevant Results |
|---|---|---|---|---|---|---|
| Epstein et al. (1977) [ | Pre-post intervention | 14 | Licorice | 100–200 g | 1–4 weeks | Serious metabolic effects due to modest licorice intake. |
| Forslund et al. (1989) [ | Pre-post intervention | 15 | Licorice | 100 g | 8 weeks | Increase in plasma ANP; Decrease in antidiuretic hormone, aldosterone, and plasma renin activity. |
| MacKenzie et al. (1990) [ | Pre-post intervention | 10 | GA | 500 mg | 8 days | Inhibition of 11β-HSD2. |
| Kageyama et al. (1992) [ | Pre-post intervention | 58 | Glycyrrhizin | 225 mg | 7 days | Changes in cortisol metabolism. |
| Bernadini (1994) [ | Pre-post intervention | Licorice root extract | 108-814 mg glycyrrhizin | 14 days | Depression of plasma renin activity favored by subclinical disease. | |
| Armanini et al. (1996) [ | Pre-post intervention | 6 | Licorice concentrate | 7 g (500 mg GA) | 7 days | Decreased activity of 11β-HSD2. |
| van Gelderen et al. (2000) [ | Double-blind randomized | 39 | GA | 0–4 mg per kg | 8 weeks | No-effect level: 2 mg/kg GA per day. |
| Sigurjónsdóttir et al. (2001) [ | Pre-post intervention | 24 | Licorice | 50–200 g | 2–4 weeks | Increase in SBP. |
| Sigurjónsdóttir et al. (2003) [ | Pre-post intervention | 25 | Licorice | 100 g | 4 weeks | Increase in SBP and DBP. Subjects with essential hypertension are more sensitive to licorice-induced rise in BP. |
| Sigurjónsdóttir et al. (2006) [ | Pre-post intervention | 25 | Licorice | 100 g | 4 weeks | The effect on aldosterone secretion differs between the genders. |
| Sobieszcyk et al. (2010) [ | Randomized double-blind | 15 | GA | 130 mg | 14 days | Attenuated vasodilatory function on VSMCs. |
| Tu et al. (2010) [ | Two-phase randomized | 16 | Glycyrrhizin | 2 × 150 mg | 14 days | Induction of CYP3A. |
| Yan et al. (2013) [ | Two-phase randomized | 14 | Glycyrrhizin (salt tablet) | 3 × 75 mg | 6 days | No induction of P-glycoprotein. |
| Leksinen et al. (2014) [ | Non-randomized, controlled open label | 20 | Licorice | 290–370 mg glycyrrhizin | 14 days | Increase in SBP, DBP, extracellular volume and amplified pressure wave reflection from the periphery. |
| Hautaniemi et al. (2017) [ | Non-randomized, controlled open label | 22 | Licorice | 290–370 mg glycyrrhizin | 14 days | Increase in SBP, DBP, central pulse pressure, extracellular fluid volume and aortic to popliteal pulse wave velocity. |
11β-HSD2: 11-β-hydrogenase type II enzyme; ANP: atrial natriuretic peptide; BP: blood pressure; CYP3A: cytochrome P450 3A4; DBP: diastolic blood pressure; GA: 18β-glycyrrhetinic acid; SBP: systolic blood pressure; VSMC: vascular smooth muscle cell.